Passage Bio

Jill Quigley, Chief Operations Officer
Philadelphia, PA
(NASDAQ: PASG)
Passage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP). The GTP conducts discovery and IND-enabling preclinical work and Passage Bio conducts all clinical development, regulatory strategy, and commercialization activities under the agreement. The company has a development portfolio of six product candidates, with the option to license eleven more, with lead programs in GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease.
www.passagebio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions